Author:
Solano-Iturri G.,García-Jiménez N.,Solano-Iturri J.D.,Blanco-Sampascual S.
Reference9 articles.
1. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease;Rostom;Gastroenterology,2006
2. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. 2013 [accessed 1 Mar 2014]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm359477.htm
3. Sprue-like enteropathy due to olmesartan and other angiotensin receptor blockers – the plot thickens;Lebwohl;Aliment Pharmacol Ther,2014
4. Systematic review: Sprue-like enteropathy associated with olmesartan;Ianiro G1;Aliment Pharmacol Ther,2014
5. Severe spruelike enteropathy associated with olmesartan;Rubio-Tapia;Mayo Clin Proc,2012